Viva Biotech Holdings (VB0) - Total Assets
Based on the latest financial reports, Viva Biotech Holdings (VB0) holds total assets worth €6.88 Billion EUR (≈ $8.05 Billion USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check Viva Biotech Holdings cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Viva Biotech Holdings - Total Assets Trend (2016–2024)
This chart illustrates how Viva Biotech Holdings's total assets have evolved over time, based on quarterly financial data. Check Viva Biotech Holdings (VB0) cash flow quality to evaluate the quality of earnings relative to operating cash generation.
Viva Biotech Holdings - Asset Composition Analysis
Current Asset Composition (December 2024)
Viva Biotech Holdings's total assets of €6.88 Billion consist of 26.6% current assets and 73.4% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 13.4% |
| Accounts Receivable | €418.95 Million | 5.9% |
| Inventory | €272.70 Million | 3.9% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €366.05 Million | 5.2% |
| Goodwill | €2.16 Billion | 30.6% |
Asset Composition Trend (2016–2024)
This chart illustrates how Viva Biotech Holdings's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see VB0 market cap overview.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Viva Biotech Holdings's current assets represent 26.6% of total assets in 2024, a decrease from 64.0% in 2016.
- Cash Position: Cash and equivalents constituted 13.4% of total assets in 2024, up from 13.2% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 35.0% of total assets, an increase from 0.0% in 2016.
- Asset Diversification: The largest asset category is goodwill at 30.6% of total assets.
Viva Biotech Holdings Competitors by Total Assets
Key competitors of Viva Biotech Holdings based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND
|
USA | $2.01 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $8.59 Billion |
|
Spyre Therapeutics Inc.
NASDAQ:SYRE
|
USA | $763.95 Million |
|
3SBio Inc
F:83B
|
Germany | €36.25 Billion |
|
Soleno Therapeutics Inc
NASDAQ:SLNO
|
USA | $608.39 Million |
|
Jiangxi Fushine Pharmaceutical Co Ltd
SHE:300497
|
China | CN¥4.48 Billion |
|
Novavax Inc
NASDAQ:NVAX
|
USA | $1.04 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF2.64 Billion |
Viva Biotech Holdings - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.76 | 0.69 | 16.21 |
| Quick Ratio | 1.44 | 0.60 | 16.13 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €754.42 Million | €-982.00 Million | €2.04 Billion |
Viva Biotech Holdings - Advanced Valuation Insights
This section examines the relationship between Viva Biotech Holdings's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.71 |
| Latest Market Cap to Assets Ratio | 0.04 |
| Asset Growth Rate (YoY) | -5.4% |
| Total Assets | €7.05 Billion |
| Market Capitalization | $301.11 Million USD |
Valuation Analysis
Below Book Valuation: The market values Viva Biotech Holdings's assets below their book value (0.04x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Viva Biotech Holdings's assets decreased by 5.4% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Viva Biotech Holdings (2016–2024)
The table below shows the annual total assets of Viva Biotech Holdings from 2016 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | €7.05 Billion ≈ $8.24 Billion |
-5.36% |
| 2023-12-31 | €7.45 Billion ≈ $8.71 Billion |
-5.95% |
| 2022-12-31 | €7.92 Billion ≈ $9.26 Billion |
-1.54% |
| 2021-12-31 | €8.04 Billion ≈ $9.41 Billion |
-1.34% |
| 2020-12-31 | €8.15 Billion ≈ $9.53 Billion |
+329.44% |
| 2019-12-31 | €1.90 Billion ≈ $2.22 Billion |
+258.71% |
| 2018-12-31 | €529.34 Million ≈ $618.85 Million |
+161.53% |
| 2017-12-31 | €202.40 Million ≈ $236.63 Million |
+98.78% |
| 2016-12-31 | €101.82 Million ≈ $119.04 Million |
-- |
About Viva Biotech Holdings
Viva Biotech Holdings, an investment holding company, engages in the provision of structure-based drug discovery services to biotechnology and pharmaceutical customers worldwide. The company provides discovery biology services, including protein expression and purification, structural biology, hit discovery, bioassay, biomolecular interaction, and pharmacology and DMPK; chemistry services, such a… Read more